

## UN EBOLA RESPONSE MPTF FINAL PROGRAMME<sup>1</sup> NARRATIVE REPORT DATE: \_\_MAY 14 2018\_\_\_\_\_

| <b>Project Number(s) and Title(s)</b><br>#57-Vaccination Cohort Study: Preventing late<br>transmission of Ebola from survivors to close contacts | Recipient Organization(s)<br>RUNO (s)<br>Project Focal Point: WHO<br>Name: Ana Maria Henao Restrepo<br>E-mail: <u>henaorestrepoa@who.int</u>                                    |  |  |  |
|--|---|--|--|--|
| Strategic Objective & Mission Critical Action(s)     Strategic Objective 2 MCA 3: Care for persons   | Implementing Partner(s)<br>Government of Guinea and a team of national and  |  |  |  |
| <ul> <li>with Ebola and Infection Control</li> <li>Strategic Objective 5 MCA 13: Multi-faceted preparedness</li> </ul>                           | international experts including Italy, UK, US, France and Germany   |  |  |  |
| Location: Guinea   | Sub-National Coverage Area: Bas-Guinea  |  |  |  |
| Programme/Project Cost (US\$)  | Programme Duration  |  |  |  |
| Total approved budget as per<br>project proposal document:   | Overall Duration: Initially 12 months   |  |  |  |
| <ul> <li>MPTF:\$1,199,603</li> </ul>   | Project Start Date: 01 April 2016   |  |  |  |
| Agency Contribution<br>o by Agency N/A   | Original End Date: 31 March 2017  |  |  |  |
| Government Contribution : N/A  | Actual End date31 March 2018Agency(ies) have operationally closed<br>the programme :No  |  |  |  |
| Other Contributions N/A  | Expected Financial Closure date: 30 September 2018  |  |  |  |
| Programme Assessment/Review/Mid-Term Eval.   | Report Submitted By   |  |  |  |
| Evaluation Completed<br>Evaluation Report - The final technical report will be<br>published in the peer review and that will be shared           | <ul> <li>Name: Marianne Kargbo</li> <li>Title: Resource Mobilization Officer</li> <li>Date of Submission 15 May 2018</li> <li>Participating Organization (Lead): WHO</li> </ul> |  |  |  |
| with MPTF.   | <ul> <li>Email address maraboma@who.int</li> <li>Signature</li> </ul>   |  |  |  |
|  | Report Cleared By   |  |  |  |
|  | <ul> <li>Name: Chris Maddock</li> <li>Date of Submission 15 May/2018.</li> </ul>  |  |  |  |
|  | <ul> <li>Date of Submission 15 May 2018.</li> <li>Participating Organization (Lead): WHO</li> </ul>   |  |  |  |
|  | <ul> <li>Email address maddekc@who.int</li> </ul>   |  |  |  |
|  | <ul> <li>Signature</li> </ul>   |  |  |  |

|  | Responsible<br>Organization(s).                  | WHO,<br>Government of<br>Guinea and a<br>team of national<br>and international<br>experts including<br>Italy, UK, US,<br>France and |  |  |   |
|--|--|---|--|--|---|
|  | Means of<br>verification                         | Interim report  | Quarterly report   | Quarterly report   | Quarterly report  |
|  | Final<br>Achievements<br>(Cumulative<br>results) | 2047  | 638<br>vaccinated day 28<br>blood sample<br>collected  | 2047 participants<br>were vaccinated for<br>2051 consenting<br>participants.   | Weekly meetings in<br>Guinea with Ebola<br>Coordination,<br>participation to<br>scientific meeting<br>organized in July<br>2016 in Monrovia<br>and another one<br>organized in<br>Geneva in<br>September 2016 |
|  | Budget<br>USD\$                                  | 100,000   | 370,562  | 370,562  | 280,000   |
|  | Target   | 1000/1500   | 100% blood sample<br>collected and<br>analyzed at 28 days  | 100% of contacts of<br>survivors who have<br>consented and<br>received the rVS<br>V vaccine  | Regular meetings with<br>key stakeholders to<br>review results and<br>provide quarterly<br>reports  |
| MCA3 – Care for persons<br>with Ebola and infection<br>control | Geographical Area                                | Guinea  | Guinea   | Guinea   | Guinea  |
| Strategic Objective to which the project contributed           | Output Indicators                                | ≠ participants recruited for the initial phase of the vaccination Programme   | ≠ blood samples of selected participants<br>systematically collected and analyzed at 28<br>day period (includes up to 500 EVD<br>survivors and up to 1500 vaccines among<br>close contacts of survivors) | ≠ contacts of survivors who have consented<br>and received the rVSV vaccine (includes up<br>to up to 1500 vaccines among close<br>contacts of survivors) | International and Guinea Staff working on<br>Study travel to meet regularly with key<br>stakeholders to review results and provide<br>quarterly reports.  |

Project Proposal Title: #57 - Vaccination Cohort Study: Preventing late transmission of Ebola from survivors to close contacts

|        | Responsible<br>Organization(s)                                | WHO and the<br>Government of<br>Guinea  |  |
|--------|---|---|--|
|        | Means of<br>verification                                      | Report of study<br>published in peer<br>review journal.   |  |
|        | Final<br>Achievement  | 100%  |  |
|        | Target  | 50%   |  |
|        | Baseline<br>In the exact area of<br>operation                 | Was not available at<br>the start of the trial.   |  |
|        | Geographical Area<br>(where the project directly<br>operated) | Guinea  |  |
| MCA 13 | Effect Indicators   | % of Reduction in Ebola disease incidence<br>among the vaccinated group of survivors<br>and close contacts in Guinea as a result of<br>the vaccination program. |  |